Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Transplantation. 2008 Dec 27;86(12):1754-61
Related Articles:
- The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantation
- Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence
- Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients
Recent Comments